Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Vertex's diversification efforts are most visible in the progress of its pain management portfolio. Read why I rate VRTX ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, ...

For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. | Despite positive early signs for its ...

Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its ...

Vertex Pharmaceuticals' (NASDAQ: VRTX) remarkable momentum came to a screeching halt this week. The big biotech stock had ...

Shares of Vertex Pharmaceuticals ( VRTX -12.76%) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came ...

CRISPR Therapeutics partnered with big biotech Vertex Pharmaceuticals ( VRTX 3.40%) on Casgevy. Although Vertex takes a ...

Amid the launch of its non-opioid pain med Journavx, Vertex Pharmaceuticals has begun an awareness-raising blitz focused on acute pain management. The new campaign stars former NFL quarterback ...